Tonix Pharmaceuticals Announces Phase 3 RESILIENT Study Of Tonmya Met Its Primary Endpoint Of Daily Pain Reduction And Achieved Statistically Significant Improvements On All Size Key Pre-Speceified Secondary Endpoints
Tonix Pharmaceuticals Announces Phase 3 RESILIENT Study Of Tonmya Met Its Primary Endpoint Of Daily Pain Reduction And Achieved Statistically Significant Improvements On All Size Key Pre-Speceified Secondary Endpoints
Tonix Pharmicals宣佈對Tonmya的3期彈性研究達到了每日減輕疼痛的主要終點，並且在所有規模的關鍵預先規定的次要終點上均取得了統計學上的顯著改善
Tonix Pharmaceuticals Announces Phase 3 RESILIENT Study Of Tonmya Met Its Primary Endpoint Of Daily Pain Reduction And Achieved Statistically Significant Improvements On All Size Key Pre-Speceified Secondary Endpoints
Tonix Pharmicals宣佈對Tonmya的3期彈性研究達到了每日減輕疼痛的主要終點，並且在所有規模的關鍵預先規定的次要終點上均取得了統計學上的顯著改善
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。